Endo Pharmaceuticals
endo.comTotal trials
105
Active
1
Phase 3
48
Total enrollment
26,556
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 1 of 1 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| EN3835 | — | — | — | — | 8 |
Next readouts
- 2026-03
Top conditions
- Edematous Fibrosclerotic Panniculopathy11
- Cellulite11
- Peyronie's Disease9
- Dupuytren's Contracture7
- Chronic Pain6
- Edematous Fibrosclerotic Panniculopathy (EFP)4
- Adhesive Capsulitis4
- Frozen Shoulder4
Frequently asked questions about Endo Pharmaceuticals
- How many clinical trials does Endo Pharmaceuticals have on ClinicalTrials.gov?
- Endo Pharmaceuticals is listed as the lead sponsor on 105 clinical trials in ClinicalTrials.gov, 1 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Endo Pharmaceuticals's trials are in Phase 3?
- 48 of Endo Pharmaceuticals's trials are in Phase 3, spread across 1 active drug program.
- What therapeutic areas does Endo Pharmaceuticals focus on?
- Endo Pharmaceuticals's most-studied conditions on ClinicalTrials.gov are Edematous Fibrosclerotic Panniculopathy, Cellulite, Peyronie's Disease, Dupuytren's Contracture, Chronic Pain.
- When are Endo Pharmaceuticals's next clinical trial readouts?
- Endo Pharmaceuticals has 1 upcoming primary-completion readout tracked here; the soonest is “Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)”, expected around 2026-03.